The U.S. Securities and Exchange Commission’s proposal to classify a broad range of exchange-traded funds as “novel ETFs” has triggered a surprisingly united complaint from parts of the investment industry: nobody seems to know exactly what “novel” means, but plenty of people are already worried about what it could mean for the $12 trillion U.S. ETF market. Comment letters from asset managers, exchanges, brokerages and other market participants argue that an overly broad label could complicate the launch of new funds and discourage financial innovation.
Wall Street Challenges SEC Over Label That Could Reshape ETF Market
The SEC began its broad review after several asset managers sought to launch funds connected to prediction markets. Rather than simply addressing those particular products, the regulator’s questions have raised a much wider issue about how novel Novel ETFs should be identified and regulated. Angela Brickl of Rafferty Asset Management argued in the firm’s submission that the category cannot be effectively defined because today’s new asset classes may quickly become yesterday’s financial fashion once the next invention arrives.
That uncertainty has become the industry’s central objection. Many issuers and exchanges are concerned that creating a separate regulatory pathway for “novel” funds could interfere with the existing process under which most new ETFs can launch automatically 75 days after filing. In the financial industry’s telling, regulators may be trying to draw a neat line around innovation at precisely the moment innovation is busy refusing to stand still — a rather inconvenient habit for something regulators are expected to define.
Novel ETFs or Novel Bureaucracy? Investors Challenge SEC Proposal
Nasdaq’s Jeffrey Davis acknowledged that some recent ETF proposals have tested the boundaries of existing rules but urged the SEC to concentrate on structural characteristics affecting investor protection and market integrity rather than relying on broad asset-class labels. That distinction matters because an ETF’s risks may depend more on how it is constructed and traded than simply on whether its underlying exposure looks unfamiliar.
Prediction-market Novel ETFs have added another layer to the dispute. Douglas Crescenzi of Adjacent Markets argued that such funds should be treated like other ETFs, while Better Markets took the opposite position, saying funds linked to prediction markets should not automatically be equated with ETFs investing in securities held by millions of Americans. The disagreement illustrates the bigger regulatory challenge facing the SEC: determine where genuinely different products require different safeguards without creating a category so broad that virtually any new ETF can be placed inside it.
For now, the SEC faces a familiar Washington problem with an unusually financial vocabulary: industry participants want innovation, regulators want investor protection, and everyone wants the rules to be clear before the next billion-dollar product arrives. The “novel ETF” debate could therefore become an important test of how the SEC under the current administration balances market innovation with regulatory oversight. OGM News will continue watching the SEC’s next moves, particularly whether the agency narrows the proposed definition, changes the ETF approval process or sends Wall Street back to the drawing board.
[…] […]